Recent 8-K filings for ACXP

• April 16, 2026, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements

  Acurx raises ~$2.5M in registered direct offering plus up to $4.6M from warrants

  Priced 825,085 shares (or pre-funded warrants) at $3.03/share for ~$2.5M gross proceeds.

• March 9, 2026, 7:59 PM ET other material materiality 0.75 positive item 5.02item 8.01item 9.01

  Acurx launches ibezapolstat pilot trial in recurrent CDI; Phase 2 showed 96% cure, no recurrence

  CEO, Executive Chairman, CFO take 10% base salary cut; director cash retainers also reduced 10%, effective April 1, 2026.

• July 17, 2025, 7:59 PM ET other material materiality 0.70 neutral item 5.07

  Acurx shareholders approve reverse split, equity plan increase, and director elections at annual meeting

  All six proposals passed at July 17 meeting; 74.38% of shares represented.

• June 20, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 8.01item 9.01

  Acurx Pharma raises $2.67M via warrant exercise; issues new warrants for ~8.89M shares

  Entered warrant inducement agreement; holder exercised ~4.45M existing warrants at reduced $0.60/share, gross proceeds $2.67M.

• May 13, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Acurx Q1 net loss narrows to $2.1M ($0.11/sh); cash $4.6M; EMA guidance for ibezapolstat Phase 3

  Net loss $2.1M ($0.11 diluted EPS) vs $4.4M ($0.28) Q1 2024; R&D fell to $0.6M, G&A to $1.6M.

• May 8, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 9.01

  Acurx Pharmaceuticals secures up to $12M equity line from Lincoln Park Capital

  Lincoln Park committed to purchase up to $12M in common stock over 24 months.

• March 28, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 3.01

  Acurx Pharma receives Nasdaq notice for non-compliance with equity requirement

  Notice based on 10-K for FY 2024; stockholders' equity fell below $2.5M minimum.

• March 18, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Acurx Pharma reports FY 2024 net loss $14.1M; cash $3.7M; EMA guidance for Phase 3

  Net loss Q4 2024 $2.8M ($0.16/diluted share) vs $5.1M ($0.37) in Q4 2023; FY 2024 net loss $14.1M ($0.87) vs $14.6M ($1.15).

• February 26, 2025, 6:59 PM ET regulatory materiality 0.60 negative item 3.01

  Acurx Pharmaceuticals receives Nasdaq minimum bid price deficiency notice; 180-day cure period

  Stock closed below $1.00 for 31 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.

• January 7, 2025, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 8.01item 9.01

  Acurx Pharmaceuticals prices $2.5M registered direct offering of 2.46M shares at $1.015

  Gross proceeds ~$2.5M from 2,463,058 shares at $1.015/share in registered direct offering.

• August 9, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Acurx Q2 net loss $4.1M, cash $6.4M; FDA confirms Phase 3 readiness for ibezapolstat

  Net loss of $4.1M ($0.26/diluted share) for Q2 2024 vs. $3.4M ($0.28) in Q2 2023.

• May 15, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Acurx Pharma Q1 net loss $4.4M; Phase 2b data positive, FDA agrees on Phase 3 plan

  Net loss of $4.4M ($0.28/diluted share) vs $2.9M loss in Q1 2023; R&D expenses $1.6M, G&A $2.8M.

• March 18, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Acurx reports Q4 net loss $5.1M; ibezapolstat Phase 2b shows 96% cure rate

  Q4 net loss $5.1M ($0.37/shr); full year net loss $14.6M ($1.15/shr).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

3 positive 2 negative 14 neutral

source · ACXP on sec.gov